Summary
Synthesizes FDA biomarker guidance, published biomarker-selected trial data, and diagnostic approval history to support biomarker-driven oncology development.
Detailed Description
The Biomarker-Driven Trial Design Pack helps sponsors integrate predictive and prognostic biomarkers into oncology clinical development programs. It draws on FDA biomarker qualification guidance, peer-reviewed literature on biomarker-selected trials, and the history of companion diagnostic approvals to provide actionable design recommendations.
The pack evaluates your candidate biomarker against established frameworks for analytical validation, clinical validation, and clinical utility. It identifies precedent biomarker-driven approvals in your therapeutic area and maps the regulatory pathway for simultaneous drug-diagnostic co-development.
Output includes a biomarker integration strategy document, an assay development roadmap aligned with FDA expectations, and a comparative analysis of biomarker-enriched versus all-comer trial designs with observed hazard ratios and regulatory outcomes.
Evidence Sources
| Source | Type | Description | Refresh |
|---|---|---|---|
| FDA Biomarker Guidance Library | REGULATORY | FDA guidance on biomarker qualification, companion diagnostics, and enrichment strategies | Monthly |
| PubMed Central Literature | LITERATURE | Published biomarker-driven oncology trial results and biomarker validation studies | Weekly |
| Diagnostic Approval History | REGULATORY | FDA PMA and 510(k) approval database for oncology companion and complementary diagnostics | Monthly |
Regulatory Mapping
Biomarker Qualification: Evidentiary Framework
Biomarkers Related to Drug or Biotechnology Product Development
Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product
Agent Transparency
When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.
Evidence Retriever
brew-retriever-v3
Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.
Domain Analyzer
brew-domain-analyst-v2
Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.
Evidence Synthesizer
brew-synthesizer-v2
Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.
Output Validator
brew-validator-v1
Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.
Sample Outputs
Biomarker Integration Strategy
PDFEnd-to-end strategy for integrating a predictive biomarker into clinical development with regulatory rationale
Assay Development Roadmap
PDFPhased plan for analytical and clinical validation of the candidate biomarker assay
Enrichment vs. All-Comer Analysis
XLSXQuantitative comparison of biomarker-enriched and all-comer trial designs with observed effect sizes
Deliverables included
- Biomarker integration strategy document (20-30 pages)
- Companion diagnostic co-development timeline
- Precedent analysis of biomarker-driven FDA approvals
- Enrichment strategy rationale with statistical modeling
- Assay validation requirements checklist
Related Disease & Biomarker Mappings
| Therapeutic Area | Disease Family | Key Biomarkers | Relevance |
|---|---|---|---|
| Solid Tumors | Non-Small Cell Lung Cancer | EGFRALKPD-L1KRAS G12C | Primary |
| Solid Tumors | Breast Cancer | HER2ER/PRBRCA1/2PIK3CA | Primary |
| Hematologic Malignancies | Acute Myeloid Leukemia | FLT3-ITDIDH1/2NPM1 | Secondary |
| Solid Tumors | Colorectal Cancer | KRAS/NRASBRAF V600EMSI-H/dMMR | Secondary |
Related Packs in Oncology
Oncology Trial Design Pack
Design smarter trials with real-world precedent data
Dose Optimization Pack (Project Optimus)
Navigate the new dose optimization paradigm with confidence
Immuno-Oncology Combination Pack
Build the regulatory case for your IO combination
Accelerated Approval Evidence Pack
Build a bulletproof accelerated approval submission
Version History
Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.
Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.
Initial draft — core evidence retrieval pipeline and output schema established.
Need a Custom Evidence Pack?
Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.
Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.